Exhibit 99.1

Alzamend Neuro, Inc. Corporate Presentation May 2024

SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the “Company” or “Alzamend”) contain “forward looking statements” within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . Forward - looking statements reflect the current view about future events . Statements that are not historical in nature, such as forecasts for the industry in which we operate, and which may be identified by the use of words like “ expects,” “assumes,” “projects,” “anticipates,” “estimates,” “we believe,” “could be,” “future,”" or the negative of these terms and other words of similar meaning, are forward - looking statements . Such statements include, but are not limited to, statements contained in this presentation relating to our business, business strategy, expansion, growth and product candidates and the timing of their development, sales and marketing strategy and capital outlook . Forward - looking statements are based on management’s current expectations and assumptions regarding our business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict and may cause actual results to differ materially from those contemplated or expressed . We caution you therefore against relying on any of these forward - looking statements . These risks and uncertainties include those risk factors discussed in Part I, “Item 1 A . Risk Factors” of our Annual Report on Form 10 - K for the fiscal year ended April 30 , 2023 (the “ 2023 Annual Report”) and other information contained in subsequently filed current and periodic reports, each of which is available on our website and on the Securities and Exchange Commission’s website ( www . sec . gov ) . Any forward - looking statements are qualified in their entirety by reference to the risk factors discussed in the 2023 Annual Report . Should one or more of these risks or uncertainties materialize (or in certain cases fail to materialize), or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned . Important factors that could cause actual results to differ materially from those in the forward - looking statements include : risks related to performing clinical studies ; the ability to initiate and complete clinical studies and report data therefrom ; whether the results from clinical studies will validate and support the safety and efficacy of our product candidates ; competition from other products ; risks in product development ; the ability to protect our intellectual property rights ; impact of any litigation or infringement actions brought against us ; market acceptance if we can commercialize our product candidates ; inability to raise capital to fund clinical trials ; and changes in government regulation . Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them . We cannot guarantee future results, levels of activity, performance or achievements . Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward - looking statements to conform these statements to actual results . All forecasts are provided by management in this presentation and are based on information available to us at this time and management expects that internal projections and expectations may change over time . In addition, the forecasts are based entirely on management’s best estimate of our future financial performance given our product candidate development and market opportunities .

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. TABLE OF CONTENTS 3 4 - 8 Company Overview Introduction 9 Alzheimer’s Disease Overview of Indications 10 Bipolar Disorder 11 12 Major Depressive Disorder Post - Traumatic Stress Disorder 13 General Scientific Overview Our Science 14 - 15 AL001 (LISPRO) – Phase I Clinical Study and Results 16 - 17 18 AL001 (LISPRO) – Phase IIA Clinical Study ALZN002 (E22W) – Phase I/IIA Clinical Study 19 - 21 AL001 (LISPRO) – Non - Clinical 22 - 23 ALZN002 (E22W) – Non - Clinical 24 Intellectual Property Specific Details 25 - 26 Competitive Landscape and Market Opportunity 27 - 29 Our Team Final Details

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION NASDAQ: ALZN 4 Biopharmaceutical Industry Small Molecule / Cell Therapy Sector 2016 Founded June 15, 2021 IPO $280k (Per our 10 - Q filed on March 25, 2024) Last Reported Cash Atlanta, Georgia (Corporate Headquarters) Location

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Lead Drug Candidate – Ionic Cocrystal of Lithium (AL001) 5 Market Opportunity Potential Replacement to Marketed Lithium Therapies Multiple Indications » 43.5 million U.S. patient population » 664 million g lobal patient population » Phase I and IIA Studies confirmed AL001 as a potential replacement to marketed lithium therapies » AL001 providing lithium at a lithium carbonate equivalent dose of 150 mg is bioequivalent to a marketed 300 mg lithium carbonate capsule » Identified a maximum tolerated dose (“MTD”), providing lithium at a lithium carbonate equivalent dose of 240 - mg, designed to be unlikely to require therapeutic drug monitoring (“TDM”) » Safety aspects of AL001 development may qualify for (505)(b)(2) pathway for FDA approval » AL001 is a patented ionic cocrystal of lithium for the potential treatment of Alzheimer's disease , Bipolar Disorder (“BD”), Major Depressive Disorder (“MDD”) and Post - Traumatic Stress Disorder (“PTSD”) » Completed a Phase I Relative Bioavailability Study in healthy human subjects in March 2022 and Reported Topline data of a Phase IIA Multiple Ascending Dose Study in patients with mild to moderate Alzheimer’s Disease and Healthy Adult Subjects in June 2023 » Received “Study May Proceed” notifications in 2H 2023 from the FDA to Initiate Phase II Clinical Trials for treatment of Bipolar Disorder, MDD, PTSD » Anticipate initiating Phase II clinical study in BD patients in 2H 2024 » Anticipate initiating Phase II clinical studies in Alzheimer's , MDD and PTSD patients in 2025

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Reference to AL001: Current Marketed Lithium – Lithium Carbonate 6 Published Clinical Efficacy Studies For Alzheimer’s Challenges Usage For BD , MDD, PTSD » Forlenza , 2011 (1) : Lithium significantly decrease CSF concentrations of P - tau and better performance on the cognitive subscale of the Alzheimer’s Disease Assessment Scale (“ADAS - cog”) (1). Forlenza , 2011: https://pubmed.ncbi.nlm.nih.gov/21525519/ » Matsunaga, 2015 (2) : Lithium significantly decreased cognitive decline as compared to placebo (2). Matsunaga, 2015: https://pubmed.ncbi.nlm.nih.gov/26402004/ » Devanand , 2017 (3) : All patients improved to varying degrees as determined by clinical judgment and/or objective rating scales, Clinical Global Impression Severity (“CGI - S”) and Change (“CGI - C”) scales, and the Neuropsychiatric Inventory (“NPI”) (3). Devanand, 2017: https://pubmed.ncbi.nlm.nih.gov/27819842/ » Narrow therapeutic window » Chronic Toxicity » Adverse Effects » Requires “TDM” » Approved by the FDA for BD and utilized off - label for MDD , PTSD , and other neurodegenerative, neurological and neuropsychiatric disorders » First mood stabilizer and first - line treatment for BD (Considered the gold standard treatment) » 524 clinical trials conducted for multiple indications (www.clinicaltrials.gov) » 5,444 published research articles (www.pubmed.gov)

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. 7 INTRODUCTION Company Overview FDA Approval Phase III Phase II Phase I Pre - Clinical Indication Product Candidate • Alzheimer’s Disease AL001 • Bipolar Disorder • Major Depressive Disorder • Post - Traumatic Stress Disorder • Alzheimer’s Disease ALZN002 • Received “Study May Proceed” notification from the FDA in September 2023 to Initiate a Phase II Clinical Trial • Anticipate initiating a Phase II clinical studies in BD patients in 2024 • Reported Topline data for the Phase IIA MAD study in June 2023 • Anticipate initiating a Phase II clinical studies in Alzheimer’s patients in 2025 • Received “Study May Proceed” notification from the FDA in November 2023 to Initiate a Phase II Clinical Trial • Anticipate initiating a Phase II clinical studies in MDD patients in 2025 • Received “Study May Proceed” notification from the FDA in December 2023 to Initiate a Phase II Clinical Trial • Anticipate initiating a Phase II clinical studies in PTSD patients in 2025 • Initiated Phase I/IIA Clinical Trial in March 2023 , paused in February 2024 and expected to resume in 2 H 2024

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Company History Current Pipeline 8 AL001 (aka LISPRO): • a patented ionic cocrystal technology delivering a therapeutic combination of lithium , salicylate and proline for the treatment of Alzheimer’s’ Disease , BD , MDD and PTSD ALZN002 (aka E22W): • a cell - based therapeutic vaccine that seeks to restore the ability of the patients’ immunological system to combat Alzheimer’s Disease. Clinical - stage biopharmaceutical company dedicated to: • Researching, developing and commercializing preventions, treatments and cures for Alzheimer's Disease, Bipolar Disorder, Major Depressive Disorder, and Post - Traumatic Stress Disorder via the two therapeutics licensed from the University of South Florida Research Foundation, Inc. , one of the top 20 institutions in the nation for patented research and their portfolio of proprietary solutions.

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzheimer’s Disease OVERVIEW OF ALZHEIMER’S DISEASE 9 Alzheimer’s Disease : Alzheimer’s Disease is an irreversible, progressive brain disorder that slowly destroys memory and cognitive skills , and eventually the ability to carry out the simplest tasks . In most people with Alzheimer’s Disease, symptoms first appear in their early to mid - 60’s. Estimates vary, but per the Alzheimer’s association, nearly 7 million Americans may have Alzheimer’s Disease, considered by many as “ the most feared” disease . Between 2000 and 2019, deaths from heart disease have decreased 7.3% while deaths from Alzheimer’s Disease have increased 145% Alzheimer’s Disease has no current cure , and only few treatments for symptoms are available today while research continues. Key Statistics: 7th leading cause of death in the United States 13 million Americans are projected to be living with Alzheimer’s Disease by 2050 In 2023, Alzheimer’s and other dementias will cost the nation $345 Billion Lithium and Alzheimer’s : Published clinical efficacy trials have reported that t reatment with lithium carbonate have resulted in reduction of biomarkers, irritability, and cognitive decline, in patients with Alzheimer's . AlZN 002 and Alzheimer’s : Compared to passive immunization treatment approaches that use foreign blood products (such as monoclonal antibodies), active immunization with ALZN 002 is anticipated to offer a more robust and long - lasting effect on the clearance of amyloid . https://www.alz.org/media/Documents/alzheimers - facts - and - figures.pdf

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Bipolar Disorder OVERVIEW OF BIPOLAR DISORDER 10 Bipolar Disorder : Bipolar Disorder is a mental illness that causes unusual shifts in a person’s mood, energy, activity levels, and concentration . The three primary types of bipolar disorders are bipolar I disorder, bipolar II disorder, and cyclothymic disorder . • Bipolar I : Characterized by episodes of mania that last at least seven days and may require hospitalization . • Bipolar II : Defined by a pattern of depressive and hypomanic episodes . Hypomania is a mood elevation that increases energy, agitation, and pressured speech . • Cyclothymic disorder : More frequent shifts between mood swings, which is called rapid cycling . The highs are consistent with hypomania symptoms and the lows are mild to moderate depression . Key Statistics: An estimated 7 Million adults in the US and over 45 Million globally experience Bipolar Disorder each year Of adults who live with Bipolar Disorder , almost 83% experience significant disruption in their physical or mental abilities The risk of suicide is extremely high in people with bipolar disorder with 15% to 17% committing suicide Lithium and B D : Lithium was the first mood stabilizer approved by the FDA and is still a first - line treatment option (considered the “ gold standard ”) for BD but is underutilized perhaps because of the need for “TDM” and patent expiration . https://www.betterhelp.com/advice/bipolar/bipolar - disorder - statistics - how - many - people - does - it - affect/ https://www.singlecare.com/blog/news/bipolar - disorder - statistics/

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Major Depressive Disorder OVERVIEW OF MAJOR DEPRESSIVE DISORDER 11 Major Depressive Disorder : Major Depressive Disorder , commonly known as clinical depression , is one of the most common mental disorders worldwide . Many different factors can contribute to a person’s depressive state and depression is often an overlapping diagnosis along with other medical conditions and/or mental disorders . The most prominent symptoms of major depression are a severe and persistent low mood, profound sadness , or a sense of despair . A major depressive episode (MDE) is a time - period characterized by symptoms of major depression . Depression is the cause of over two - thirds of the 30 , 000 reported suicides in the U . S . each year . Key Statistics: An estimated 21 Million adults in U.S. had at least one major depressive episode in 2021. This number represented 8.3% of all U.S. adults. An estimated 5.0 million adolescents aged 12 to 17 in the United States had at least one major depressive episode. This number represented 20.1% of the U.S. population aged 12 to 17. Lithium and MDD : Although lithium products do not have an FDA - approved indication for MDD, it has been utilized off - label for MDD . While a wide variety of medications have been used historically for augmentation of an antidepressant in MDD, lithium is one of the few agents that has demonstrated efficacy in multiple randomized controlled trials . https://www.nimh.nih.gov/health/statistics/major - depression https://www.dbsalliance.org/education/depression/statistics https://www.singlecare.com/blog/news/depression - statistics/

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Post - Traumatic Stress Disorder OVERVIEW OF POST TRAMATIC STRESS DISORDER 12 Post - Traumatic Stress Disorder : PTSD is a mental and behavioral disorder that can develop because of exposure to a traumatic event , such as sexual assault, warfare, traffic collisions, child abuse, domestic violence, or other threats on a person’s life . Symptoms may include disturbing thoughts, feelings, or dreams related to the events, mental or physical distress in response to trauma - related cues, attempts to avoid trauma related cues, alterations in the way a person thinks and feels, and an increase in the fight - or - flight response . These symptoms last for more than a month after the event . A person with PTSD is at a higher risk of suicide and intentional self - harm . Key Statistics: About 5 out of every 100 adults (or 5 % ) in the U . S . has PTSD in any given year . In 2020 , about 13 million Americans had PTSD . Veterans are more likely to have PTSD than civilians . Veterans who deployed to a war zone are also more likely to have PTSD than those who did not deploy . Lithium and PTSD : Although lithium products do not have an FDA - approved indication for PTSD, it has been utilized off - label for PTSD . Treatment with low doses ( 300 – 600 mg/day) of lithium carbonate have been reported to provide effective treatment in reduction of inappropriate anger, irritability, anxiety, and insomnia in patients with PTSD . https://www.nimh.nih.gov/health/topics/post - traumatic - stress - disorder - ptsd https://www.ptsd.va.gov/understand/common/common_adults.asp https://www.nhs.uk/mental - health/conditions/post - traumatic - stress - disorder - ptsd/overview/

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Our Science GENERAL SCIENTIFIC OVERVIEW 13 Status Strength Synopsis Therapeutic Drug ▪ Reported Topline data of Phase IIA Multiple Ascending Dose Clinical Trial in June 2023. (www.clinicaltrials.gov, identifier: NCT05363293 ) ▪ Received “Study May Proceed” notification from the FDA in 2H 2023 to Initiate a Phase II Clinical Trial to treat Bipolar Disorder, Major Depressive Disorder and Post - Traumatic Stress Disorder ▪ Anticipate initiating a Phase II Clinical trial in patients with BD in 2H 2024 ▪ Anticipate initiating a Phase II Clinical trial in patients with Alzheimer's, MDD, and PTSD in 2025 ▪ Exclusive license for ionic cocrystal delivery system to treat Alzheimer’s Disease ▪ Potential for “breakthrough therapy” designation from FDA ▪ Seeking a 505(b)(2) clinical trial pathway from FDA ▪ Formulation may importantly expand the range of therapeutic categories amenable to lithium treatments, with enhanced safety ▪ Has the potential of becoming the replacement for all lithium therapies on the market ▪ Use of patented ionic cocrystal technology delivering a therapeutic combination of Lithium, Proline, and Salicylate ▪ Lithium as a treatment of agitation and other possible symptoms in patients with indication of Alzheimer’s Disease ▪ Other potential indications: Dementia, Amyotrophic Lateral Sclerosis (“ALS”), Huntington’s Disease, multiple sclerosis, Parkinson’s Disease and traumatic brain injury (“TBI”), to more psychiatric conditions such as BD, MDD, mania, PTSD and suicidality AL001 ▪ Phase I/IIA Clinical Trial Initiated in March 2023 (www.clinicaltrials.gov, identifier: NCT05834296 ), paused in February 2024 and expected to resume in 2H 2024 ▪ Adjuvant - free therapeutic vaccine designed for the treatment and prophylactics of Alzheimer’s Disease ▪ Potential for “breakthrough therapy” designation from FDA ▪ Antibody responses induced after one inoculation (Pre - Clinical) and lasted for 4 months ▪ Inflammation cytokines like IL1 and TNF.alpha, which are considered being related to inflammation didn't increase with antibody level increase ▪ A patented method using a mutant peptide sensitized cell as a cell - based therapeutic vaccine that reduces beta - amyloid plaque and seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s Disease ALZN002

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 Phase I Trial 14 Status Description Study Title Study No. Completed • To assess the relative bioavailability of the AL001 lithium formulation relative to a marketed lithium carbonate formulation in healthy subjects for the purpose of determining potential clinically safe and effective AL001 dosing in future studies. • To characterize safety and tolerability of the tested formulations under the conditions of this study. A randomized, balanced, Phase I, single - dose, open - label, two - treatment, two - period, two sequence, crossover, relative bioavailability study to investigate lithium pharmacokinetics and safety of AL001 formulation compared to a marketed immediate release lithium carbonate formulation in healthy subjects. AL001 - ALZ01 (US) OUR SCIENCE - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Safety/Tolerability: Primary Endpoint Met Select Results from Phase I Trial 15 » AL001 was shown to be safe and well - tolerated in healthy adult subjects » No serious adverse events and no deaths were reported during the trial » T he safety profiles of both AL001 and the marketed lithium carbonate capsule were benign » No clinically significant abnormal findings in electrocardiograms were noted during the trial » AL001 salicylate plasma concentrations were observed to be well tolerated and consistently within safe limits » Dose - adjusted relative bioavailability analyses of the rate and extent of lithium absorption in plasma indicated that AL001 1050 mg (lithium content equivalent to150 mg lithium carbonate) is bioequivalent to a marketed 300 mg lithium carbonate capsule and the shapes of the lithium plasma concentration versus time curves are similar OUR SCIENCE - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 Phase IIA Trial 16 Status Description Study Title Study No. • Reported Topline data of Phase IIA Multiple Ascending Dose Clinical Trial in June 2023 . (www.clinicaltrials.gov, identifier: NCT05363293 ) • Primary: To evaluate the safety and tolerability of AL001 under multiple - dose, steady - state conditions in Alzheimer’s subjects and healthy adult subjects • Secondary: To characterize the “MTD” of AL001 in subjects with mild to moderate Alzheimer's Disease and healthy adult subjects • Exploratory: To explore the difference in pharmacokinetic profile between the non - elderly vs. elderly subjects (healthy subjects only). For Alzheimer’s Disease subject cohorts (Cohorts 1,2b, 3b, 4b, and 5b), determination of qualitative and quantitative evaluations of Alzheimer’s Disease subject desirable characteristics for future Phase II and III clinical studies to: • Facilitate recruitment into subsequent AL001 clinical trials • Facilitate trial - adherence to completion of study requirements including treatment adherence A Multiple - dose, Steady - state, Double - blind, Ascending Dose Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients with Mild to Moderate Alzheimer’s Disease and Healthy Adult Subjects AL001 - ALZ02 (US) OUR SCIENCE - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Identify Maximum Tolerated Dose: Established Topline Results from Phase IIA Trial 17 » Identified dose of lithium at a lithium carbonate equivalent dose of 240 mg 3 - times a day (“TID”), is designed to be unlikely to require lithium TDM » No serious adverse events and no deaths were reported during the trial » MTD is risk mitigated for the purpose of treating fragile populations , such as Alzheimer's patients » Goal is to replace a 300 mg TID lithium carbonate dose for treatment of BD with a 240 mg TID AL001 lithium equivalent, which represents a daily decrease of 20% of lithium given to a patient » Results identified a safe and appropriate dose to explore the potential for AL001 to distribute more lithium to the brain but at a lower systemic exposure, resulting in an improved safety profile compared to currently marketed lithium salts OUR SCIENCE - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. ALZN002 Phase I/IIA Trial 18 Status Description Study Title Study No. Phase I/IIA Clinical Trial Initiated in March 2023 ( www.clinicaltrials.gov, identifier: NCT05834296 ), paused in February 2024 and expected to resume in 2H 2024 • Primary: • To assess the safety and tolerability of ALZN002 compared with placebo when administered as IV infusion and ID injection in subjects with mild to moderate AD • Secondary: • To evaluate the immunogenicity of ALZN002 specific to generation of anti - A β antibodies • To determine the effect of ALZN002 on Amyloid - Related Imaging Abnormalities (ARIA) as a putative biomarker of treatment safety • Exploratory: • To assess the utility of multiple immune biomarkers as surrogates for safety and efficacy of ALZN002. • To assess the preliminary efficacy of ALZN002 treatment on amyloid markers as observed by amyloid positron emission tomography (PET). A Randomized, Double - blind, Placebo - controlled, Parallel group, Phase I/IIA Study to Assess the Safety, Tolerability, and Efficacy of Autologous Amyloid Beta Mutant Peptide - Pulsed Dendritic Cells (ALZN002) in Subjects with Mild - to - Moderate Dementia of the Alzheimer’s Type ALZN002 - 01(US) OUR SCIENCE - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO ) 19 • AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium , salicylate, and proline. • AL001 exhibits improved non - clinical pharmacokinetics and bioavailability compared to the currently FDA approved lithium drugs on the market • AL001 exhibits improved non - clinical brain bioavailability , without demonstrating an initial spike in lithium concentration that is associated with negative side effects of treatment • AL001 nonclinical brain penetration/ persistence may translate to patients resulting in lithium dose sparing properties with enhanced overall safety and reduced or eliminated need for “TDM”. • Narrow therapeutic window that requires regular blood monitoring of plasma lithium levels and blood chemistry by a clinician to mitigate adverse events • Multiple administrations throughout the day are required to safely reach therapeutic plasma concentrations • Suffer from chronic toxicity, poor physicochemical properties and poor brain bioavailability 0 2 4 6 8 10 12 14 2 hrs 24 hrs 48 hrs 72 hrs Lithium (µg/g) Plasma Lithium Levels Lithium Carbonate AL001 (LISPRO) 0 2 4 6 8 10 2 hrs 24 hrs 48 hrs 72 hrs Lithium (µg/g) Brain Lithium Levels Lithium Carbonate AL001 (LISPRO) OUR SCIENCE – NON - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO) 20 The results of our preclinical studies, conducted from May 2016 to June 2017 , are summarized below : • AL 001 had no effect on renal COX 2 activity ( Tg - Ctrl vs . AL 001 : p > 0 . 05 ), a biomarker of renal toxicity, while markedly reducing abnormal biomarkers associated with Alzheimer’s Disease by 50 % ; beta - amyloid pathology, tau phosphorylation and neuro - inflammation ( Tg - Ctrl vs . AL 001 : p < 0 . 01 )(FIGS . 14 A/B - 15 A/B) . • AL 001 treatment did not induce tissue pathological damage in the heart, kidneys, liver or lungs by a general autopsy ( Tg - Ctrl vs . AL 001 : p > 0 . 05 ) . In contrast, equimolar doses (using a similar structure of moles but different active pharmaceutical ingredient) of lithium carbonate enhanced renal COX 2 expression while having little or no impact on Alzheimer’s Disease pathology ( Tg - Ctrl vs . LC : p < 0 . 01 ) . • AL 001 , at the effective dose, yielded 50 % higher lithium levels (LC vs . AL 001 ; p < 0 . 01 ) in the brain compared with equimolar doses of lithium carbonate (AL 001 vs . LC ; p < 0 . 05 ), while producing low nontoxic steady state levels in the body . (LI 2 CO 3 ) (LISPRO/Tg2576) (Control) (LI 2 CO 3 ) (Control) (LISPRO) FIG. 14A FIG. 14A & 14B: Beta Amyloid Burden FIG. 15A FIG. 15A & 15B: Tau Phosphorylation Burden OUR SCIENCE – NON - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO) 21 • Our pre - clinical studies encompassed the treatment of 28 transgenic (or genetically modified) and 10 non - transgenic mice with lithium carbonate and AL001. • Female APPSWE/PS1dE9 mice at 4 months of age were orally treated with LISPRO (LP), Lithium Salicylate (LS), or Lithium Carbonate (LC) for 9 months followed by determination of body weight , growth of internal organs , and cognitive and non - cognitive behavior . • Untreated age - matched non - transgenic littermates served as Wild - Type (WT) controls. • No significant differences in body weight, brain, heart, lung, spleen, liver or kidney were found between lithium treated and untreated APPSWE/PS 1 dE 9 cohorts ( Tg - Ctrl vs . AL 001 : p > 0 . 05 ) . • AL 001 treatment improved cognitive function by 50 % ( Tg - Ctrl vs . AL 001 : p < 0 . 01 ), in comparison with the control group, through behavioral tests administered to mice with Alzheimer’s Disease . The tests resulted in 50 % lower escape latency ( Tg - Ctrl vs . AL 001 : p < 0 . 01 ) during the training and probe trial of the Morris water maze test and 50 % longer contextual freezing time ( Tg - Ctrl vs . AL 001 : p < 0 . 05 ) during the fear conditioning test . • AL 001 treatment reduced depression by 25 % ( Tg - Ctrl vs . AL 001 : p < 0 . 001 ), as assessed by the tail suspension test, and irritability by 50 % ( Tg - Ctrl vs . AL 001 : p < 0 . 01 ), as assessed by the touch escape test . • Continued AL 001 treatment prevented cognitive deficits , depression and irritability and, compared to lithium carbonate treatments, was superior in improving associative learning and memory (LC vs . AL 001 : p < 0 . 05 ) and in reducing irritability (LC vs . AL 001 : p < 0 . 01 ), supporting the potential of this lithium formulation for the treatment of Alzheimer’s Disease . The Results OUR SCIENCE – NON - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of ALZN002 (aka E22W) 22 • Our goal is to develop an Alzheimer’s Aß vaccine candidate that will be devoid of the problems associated with current vaccine therapies. Our studies concluded the successful vaccination of mice with adjuvant - free mutated beta amyloid peptides have significant advantages over both native beta amyloid and the use of adjuvant. • 10 weeks old female BALB/c mice were housed in Varian standard cages including amber igloos and vaccinated when 14 weeks old. • Differently mutated Aß 1 - 42 peptides were used for each group and a 1times.PBS (also containing 10% DMSO) as a control group . • Mice vaccinated with various mutated Aß 1 - 42 peptides induce antibody responses after two inoculations, while no antibody can be detected in the control group (FIG. 5A). • All antibodies induced by the peptide injection bind to the same epitope . There is no difference in recognition between the various anti - sera and peptides such that all anti - sera recognize the 1 - 16 epitope on all peptides. • Demonstrate definite advantages over previous vaccination protocols, which strongly support our Adjuvant - Free Vaccine Hypothesis. • The data clearly show that wild type and mutated Aß peptide administrated without adjuvant induce a strong and long - lasting antibody response . • The first use of adjuvant - free Aß as Alzheimer's vaccine and demonstration that T - cell epitope mutation will contribute to either Th1 or Th2 response. Those peptides will have outstanding promise for the treatment of Alzheimer’s Disease. The Results OUR SCIENCE – NON - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of ALZN002 (aka E22W) 23 • We illustrated our result by using Aß peptide pulsed Dendritic Cells (“DC”) as a vaccine in Tg APP/PS1 mice. • Aß 1 - 42 with different mutation were synthesized and designed as PWT (Wild - Type Abeta1 - 42), PFM ( Aß with Flemish mutation), PDM ( Aß with Dutch mutation), PFDM ( Aß with both Flemish and Dutch mutation), P22W ( Aß with a new mutation at amino acid 22), P24G ( Aß with mutation at amino acid 24). • There is no antibody production after two injections of DCs sensitized with Wild - Type Aß peptide (PWT). However, all other groups that received DCs sensitized with mutant Aß can induce antibody response even with only one vaccination . The antibody titer can reach as high as 1:16000 with only two inoculations. • Our result indicated that the antibody could last at least 4 months . • Inflammation has been considered as the very important safety issue in Alzheimer’s Disease vaccine. Therefore, we have checked the antibody level to these peptide vaccinated mice. There is no difference for both Th1 and Th2 cytokine among all these groups at the same time point (P>0.05). It is worth noting that inflammation cytokines like IL1 and TNF.alpha . which are considered being related to inflammation didn't increase with antibody level increase . However, Th2 cytokine as IL4 increase with the antibody increasing (See FIG. 4). The Results OUR SCIENCE – NON - CLINICAL

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Alzamend Neuro’s Intellectual Property (Licensed Patents) ALZAMEND NEURO 24 Patent # Expiration Date Date Issued Date Filed Therapeutic Drug Patent Type Title of Patent 9,603,869 05/21/2036 03/28/2017 05/21/2016 AL001 (LISPRO) Method of Use Lithium Cocrystals and an Additional Neuropsychiatric Agent for Treatment of Neuropsychiatric Disorders 9,840,521 04/18/2034 12/12/2017 04/18/2014 AL001 (LISPRO) Composition of Matter Organic Anion Lithium Ionic Cocrystal Compounds and Compositions 8,188,046 02/12/2028 05/29/2012 10/12/2007 ALZN002 (E22W) Composition of Matter Amyloid Beta Peptides and Methods of Use

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Top Alzheimer’s Disease Drugs on the Market COMPETITIVE LANDSCAPE Aricept Exelon Namenda Leqembi A Aricept – Eisai Co., Ltd., Financial Results for Fiscal 2022(3/31/2023 for JPY FX) https://www.eisai.com/ir/library/settlement/pdf/e2023Q4_51.pdf B Exelon – Knight Therapeutics 2022 Annual Report(12/30/22 for CAD FX) https://knighttx.com/Investors - Content/Financial_reports/2022/Knight - AnnualReport2022 - upd.pdf C Namenda – Allergan 2019 Annual Report www.annualreports.com/HostedData/AnnualReports/PDF/NYSE_AGN_2019.pdf D Biogen & Eisai www.leqembi.com Costs Per Patient: www.goodrx.com 1996 Year Approved: $3,454,000,000 Peak Revenue Per Year: $6,312 Cost Per Patient Per Year (2023) : $97,800,000 Total Revenue (2022) A : 2000 Year Approved: $1,067,000,000 Peak Revenue Per Year: $8,532 Cost Per Patient Per Year (2023): $11,275,000 Total Revenue (2022) B : 2003 Year Approved: $2,575,000,000 Peak Revenue Per Year: $5,556 Cost Per Patient Per Year (2023): $22,800,000 Total Revenue (2019) C : 2023 Year Approved: N/A Peak Revenue Per Year: $26,500 Cost Per Patient Per Year (2023): N/A Total Revenue D : 25

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Market Opportunity for AL001 and ALZN002 COMPETITIVE LANDSCAPE 26 Global (Including US) United States Patient Population 280 Million² 21 Million¹ MDD 284 Million² 9 Million¹ PTSD 55 Million² 6.5 Million¹ Alzheimer ’s Disease 45 Million² 7 Million¹ BD 664 Million 43.5 Million Total Patient Population Major Depressive Disorder: 1. https://www.nimh.nih.gov/health/statistics/major - depression 2. https://www.who.int/news - room/fact - sheets/detail/depression PTSD: 1. https://www.nimh.nih.gov/health/statistics/post - traumatic - stress - disorder - ptsd 2. https://www.who.int/news/item/06 - 08 - 2013 - who - releases - guidance - on - mental - health - care - after - trauma#:~:text=An%20estimated%203.6%25%20of%20the,previous%20year%2C%20the%20study%20showed Alzheimer’s: 1. https://www.alz.org/media/Documents/alzheimers - facts - and - figures.pdf 2. https://www.alzint.org/about/dementia - facts - figures/dementia - statistics/ Bipolar Disorder: 1. https://www.nimh.nih.gov/health/statistics/bipolar - disorder 2. https://www.who.int/news - room/fact - sheets/detail/mental - disorders

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Leadership Team ALZAMEND NEURO 27 Stephan Jackman Chief Executive Officer and Director 20+ years multi - industry experience, specialized in Biotech and Pharmaceutical Kenneth S. Cragun Senior Vice President of Finance 30+ years SEC reporting, CFO of publicly - traded company on Nasdaq, multi - industry experience, including Biotech and Healthcare Henry Nisser Executive Vice President, General Counsel and Director 20+ years experience, U.S. securities compliance, M&A, equity/debt financings and corporate governance David J. Katzoff Chief Financial Officer 30+ years multi - industry experience, including Healthcare and Technology

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Scientific Advisory Board ALZAMEND NEURO 28 Thomas M. Wisniewski, M.D. Director, NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment 300+ Peer - Reviewed Medical Journal Publications (19 U.S. Patents Issued) Leads a Research Laboratory Continuously Funded by the National Institutes of Health for 20+ Years Eric McDade, D.O. Associate Director, DIAN Trials Unit & Clinical Trials Leadership, Washington University School of Medicine Associate Professor of Neurology, Washington University School of Medicine 157+ Peer - Reviewed Journal Publications Terri Hunter, Ph.D. Technology Transfer and Partnerships Specialist, U.S. Department of Veterans Affairs 20+ years Experience, Research and Technology Transfer and Partnerships Ph.D. in Medical Sciences from the University of South Florida College of Medicine

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Lynne Fahey McGrath, Ph.D. Regulatory Affairs and Product Development Consultant 30+ years experience, Biotech and Pharmaceuticals M.P.H./Ph.D., Public Health from UMDNJ – Robert Wood Johnson Medical School Jeffrey Oram Principal at Godby Realtors 25+ years multi - industry experience, Investments, Real Estate and Technology Andrew H. Woo, M.D., Ph.D. Practicing physician at Santa Monica Neurological Consultants, Assistant Clinical Professor of Neurology at the David Geffen School of Medicine at UCLA and Cedars - Sinai Medical Center 20+ years experience in Neurology Mark Gustafson, C.P.A. Chief Financial Officer of PharmaKure Limited 30 + years multi - industry experience as an active CPA, specialized in Biotech, Energy and Technology Alzamend Board of Directors 29 William B. Horne Chairman of Alzamend Chief Executive Officer of Ault Alliance 25+ years Financial Industry experience, prior “Big 4” auditor and healthcare executive Stephan Jackman Chief Executive Officer and Director 20+ years multi - industry experience, specialized in Biotech and Pharmaceutical Henry Nisser Executive Vice President, General Counsel and Director 20+ years experience, U.S. securities compliance, M&A, equity/debt financings and corporate governance Milton “Todd” Ault, III Vice Chairman of Alzamend Founder of Alzamend, Executive Chairman of Ault Alliance, the Singing Machine Company, and MTIX International 30+ years Financial Industry experience, activist investor ALZAMEND NEURO

CONTACT US 3480 Peachtree Road NE 2 nd Floor, Suite 103 Atlanta, GA 30326 +1 (844) 722 - 6333 Info@alzamend.com www.alzamend.com